



Commercial/Healthcare Exchange PA Criteria

Effective: July 24, 2019

Prior Authorization: Evekeo (amphetamine sulfate)

Products Affected:

Evekeo (amphetamine sulfate) oral tablet

Medication Description:

Evekeo (amphetamine sulfate) tablet is racemic amphetamine for the treatment of ADHD, narcolepsy and short term weight management. Both isomers of amphetamine show different pharmaceutical properties, with the L-isomer exhibiting more cardiovascular effects and less neurologic excitation. Side effect profile is similar to other stimulants used in the treatment of ADHD and narcolepsy. Evekeo tablets carrier a warning regarding its possible cardiovascular effects as well as other common issues with stimulants. Like other stimulants, Evekeo may also cause dependence

Covered Uses:

1. Narcolepsy
2. Attention Deficit Disorder with Hyperactivity
3. Exogenous Obesity (**benefit exclusion**) **Medications for weight loss are not a covered benefit and are excluded from coverage**

Exclusion Criteria:

Evekeo has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval in the following circumstances.

1. Indication of Exogenous Obesity: Medications for weight loss are not a covered benefit and are excluded from coverage
2. Patient with advanced arteriosclerosis
3. Patient with moderate to severe Hypertension
4. Patient with Hyperthyroidism
5. Patient with history of drug abuse
6. Patient with use of monoamine oxidase inhibitors within 14 days
7. Patient is in an agitated state
8. Patient is pregnant or nursing

Required Medical Information:

1. Diagnosis
2. **Attention Deficit Disorder with Hyperactivity/Narcolepsy**
 - a. Documented history of previously used treatments

Age Restrictions:

1. **Attention Deficit Disorder with Hyperactivity**
 - a. Under 3 years of age

Prescriber Restrictions:

- Narcolepsy
- In consultation with sleep specialist

Coverage Duration:

1. **Narcolepsy**
 - a. 12 months
2. **Attention Deficit Disorder with Hyperactivity**
 - a. 12 months

Other Criteria:

1. **Narcolepsy**
 - A) Patient has previous use of 1 preferred stimulants used in the treatment of Narcolepsy; **AND**
 - B) Patient does not currently have contraindication to use of stimulants
2. **Attention Deficit Disorder with Hyperactivity**
 - A) Patient has previous use of 2 preferred stimulants used in the treatment of ADHD; **AND**
 - B) Patient does not currently have contraindication to use of stimulants

References:

1. Childress, Ann C. et al. “The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.” *Journal of Child and Adolescent Psychopharmacology* 25.5 (2015): 402–414. *PMC*. Web. 26 Dec. 2015.
2. Micromedex solutions “Evekeo (amphetamine sulfate)” drug profile 26 Dec. 2015
<http://www.micromedexsolutions.com>
3. Heal, David J et al. “Amphetamine, Past and Present – a Pharmacological and Clinical Perspective.” *Journal of Psychopharmacology (Oxford, England)* 27.6 (2013): 479–496. *PMC*. Web. 26 Dec. 2015.
4. Evekeo (amphetamine sulfate) [prescribing information] Atlanta, GA Arbor Pharmaceuticals LLC; May 2015
<https://www.evekeo.com/assets/evekeo-pi.pdf>
5. Morgenthaler, Timothy et al. “Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin An American Academy of Sleep Medicine Report.” *Sleep*. 2007 Dec 1; 30(12): 1705–1711. *PMC*. Web. 26 Dec. 2015.
6. Jensen, Michael et al. “2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults.” *Circulation*. 2014; 129: S102-S138

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date

Last Res.7.24.2019

1	New Policy	New Policy, Removed Evekeo from CCI ADHD policy, adopted EH policy, removed coverage criteria for obesity diagnosis	All	7/24/2019
---	------------	---------------------------------------------------------------------------------------------------------------------	-----	-----------

